Drug Patents owned by Melinta Therap

1. List of Kimyrsa drug patents

KIMYRSA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9649352 MELINTA THERAP High purity oritavancin and method of producing same
Jul, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8420592 MELINTA THERAP Methods of treatment using single doses of oritavancin
Aug, 2029

(6 years from now)

US9682061 MELINTA THERAP Methods of treating bacterial infections using oritavancin
Apr, 2030

(6 years from now)

Do you want to check out KIMYRSA patents from before 2022?
Exclusivity Exclusivity Expiration
New Product (NP) Mar 12, 2024
New Chemical Entity Exclusivity (NCE) Aug 6, 2019
Generating Antibiotic Incentives Now (GAIN) Aug 6, 2024

Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient

NCE-1 date: 2023-08-07

Market Authorisation Date: 12 March, 2021

Treatment: Treatment of acute bacterial skin and skin structure infections with a single dose of 1200mg oritavancin or its single dose equivalent

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

KIMYRSA family patents

14

United States

4

China

4

European Union

3

Canada

3

Japan

3

Australia

2

New Zealand

2

Brazil

EA

2

EA

2

Mexico

2

Hungary

1

Poland

1

Spain

1

Netherlands

1

Hong Kong

1

Norway

1

Denmark

2. List of Orbactiv drug patents

ORBACTIV's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8420592 MELINTA THERAP Methods of treatment using single doses of oritavancin
Aug, 2029

(6 years from now)

US9682061 MELINTA THERAP Methods of treating bacterial infections using oritavancin
Apr, 2030

(6 years from now)

US9649352 MELINTA THERAP High purity oritavancin and method of producing same
Jul, 2035

(12 years from now)

Do you want to check out ORBACTIV patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 6, 2019
Generating Antibiotic Incentives Now (GAIN) Aug 6, 2024

Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient

NCE-1 date: 2023-08-07

Market Authorisation Date: 06 August, 2014

Treatment: Treatment of bacterial skin and skin structure infections using a single dose; Treatment of bacterial skin and skin structure infections

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

ORBACTIV family patents

14

United States

4

China

4

European Union

3

Canada

3

Japan

3

Australia

2

New Zealand

2

Brazil

EA

2

EA

2

Mexico

2

Hungary

1

Poland

1

Spain

1

Netherlands

1

Hong Kong

1

Norway

1

Denmark

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in